id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
dti-2637	Babyshkina, Nataliya; Popova, Nataliya; Grigoryev , Evgeny; Dronova , Tatyana; Gervas , Polina; Dobrodeev , Alexey; Kostromitskiy , Dmitry; Goldberg , Victor; Afanasiev , Sergei; Cherdyntseva , Nadejda	Long-term response with the atypical reaction to nivolumab in microsatellite stability metastatic colorectal cancer: A case report	2024	4	.pdf	application/pdf	2507	135	45	Focal nodules in the lung at start of nivolumab treatment (A); 5 months after nivolumab treatment, reduction of lung nodules (B) and para-aortic lym- ph node lesion up to 12 mm (C); 8 months after nivolumab tre- atment, disappearance of lung lesions (D) and lack of growth of para-aortic lymph node lesion (E); increase of para-aortic lym- ph node lesion 40 months after nivolumab treatment (F). Nivolumab (Opdivo) is a human immunoglobulin G4 monoclonal antibody that blocks the interaction between the programmed cell death 1 (PD-1) receptor and its ligands 1/2 (PD-L1/PD-L2), leading to inhibition of T-cell proliferation, cytokine secretion, and enhanced immune response.	cache/dti-2637.pdf	txt/dti-2637.txt